Travere Therapeutics, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 45.06 million compared to USD 29.34 million a year ago. Net loss was USD 90.17 million compared to USD 65.82 million a year ago. Basic loss per share was USD 1.18 compared to USD 1.03 a year ago.
For the full year, revenue was USD 145.24 million compared to USD 109.46 million a year ago. Net loss was USD 111.4 million compared to USD 278.48 million a year ago. Basic loss per share was USD 1.5 compared to USD 4.37 a year ago.